Cancer/Tumor Profiling Market Report by Cancer Type, Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Immunohistochemistry, In-Situ Hybridization, Microarray, and Others), Technique, Application, and Region 2024-2032
세계 암/종양 프로파일링 시장 규모는 2023년 115억 달러에 달했습니다. 향후 IMARC Group은 시장이 2032년까지 246억 달러에 이르렀으며 2024-2032년 사이에 8.6%의 성장률(CAGR)을 나타낼 것으로 예측했습니다.
암/종양 프로파일링은 바이오마커 시험으로도 알려져 있으며, 종양 조직 샘플에서 특정 단백질, 유전자, 유전자 변이(변화) 및 기타 바이오마커를 확인하는 데 사용되는 실험실에서의 시험 또는 절차를 가리킵니다. 환자의 종양 경로가 사용 가능한 표적 요법과 일치하는지 여부를 결정할 때 종양 의사를 지원합니다. 또한 일상적인 진단, 치료 방침의 결정, 질환의 중증도나 유전체의 축적별 개인에 맞춘 치료 계획이나 치료법의 개발에도 도움이 됩니다. 암/종양 프로파일링은 개인화된 의료, 연구, 바이오마커 발견, 스크리닝 및 진단 기술 개발에도 광범위하게 적용되고 있습니다.
암/종양 프로파일링 시장 동향 :
암/종양 프로파일링은 종양학 연구 및 약제 설계, 발견, 개발 과정에서 바이오마커의 발견에 널리 이용되고 있습니다. 그 결과, 세계에서 암이 널리 만연하고 있는 것이 시장 성장을 가속하는 주요인이 되고 있습니다. 이 외에도 진단 및 종양 프로파일 링을위한 바이오 마커에 대한 관심 증가와 대중의 맞춤형 의료에 대한 선호도의 변화가 제품 수요를 증가 시켰습니다. 게다가 종양의 검출과 동정에 걸리는 시간을 단축하기 위한 고도의 기술 개발을 위해, 암 연구에 대한 정부의 자금 원조나 지원이 대폭 증가하고 있습니다. 이와 함께 차세대 시퀀싱(NGS) 등 분자 생물학 기술의 최근 진보가 암/종양 프로파일링의 채용을 가속화하고 있습니다. 게다가 제약기업과 생명공학기업에 의한 신약치료 및 신약설계기술의 상시를 향한 연구개발(R&D) 활동에 대한 투자가 증가하고 있는 것도 시장의 성장을 뒷받침하고 있습니다. 임상시험 건수 증가, 면역측정기술 채택 확대, 유리한 상환정책, 의료 인프라 개선, 기술 진보 등 기타 요인들도 시장에 밝은 전망을 가져오고 있습니다.
이 보고서에서 다루는 주요 질문
- 2023년 세계 암/종양 프로파일링 시장 규모는?
- 2024-2032년 세계의 암/종양 프로파일링 시장의 예상 성장률은?
- 세계의 암/종양 프로파일링 시장에 준 COVID-19의 영향은?
- 세계의 암/종양 프로파일링 시장을 견인하는 주요 요인은?
- 세계의 암/종양 프로파일링 시장의 암 유형별 내역은?
- 세계의 암/종양 프로파일링 시장의 주요 지역은?
- 세계 암/종양 프로파일 링 시장의 주요 진출기업/기업은?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사의 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 암/종양 프로파일링 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 분석 : 암 유형별
제7장 시장 분석 : 기술별
- 차세대 시퀀싱(NGS)
- 중합효소 연쇄반응(PCR)
- 면역조직화학(IHC)
- 제자리 부합법(ISH)
- 마이크로어레이
- 기타
제8장 시장 분석: 수법별
제9장 시장 분석 : 용도별
- 맞춤형 의료
- 진단
- 바이오마커의 발견
- 예측
- 기타
제10장 시장 내역: 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제11장 SWOT 분석
제12장 밸류체인 분석
제13장 Porter's Five Forces 분석
- 개요
- 구매자의 협상력
- 공급기업의 협상력
- 경쟁도
- 신규 참가업체의 위협
- 대체품의 위협
제14장 가격 분석
제15장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업 프로파일
- Abbott Laboratories
- Becton Dickinson and Company
- Caris Life Sciences
- Exact Sciences Corporation
- F. Hoffmann-La Roche Ltd
- Hologic Inc.
- HTG Molecular Diagnostics Inc.
- Illumina Inc.
- Laboratory Corporation of America Holdings
- NeoGenomics Laboratories
- Qiagen NV
- Siemens AG
- Sysmex Corporation
JHS
The global cancer/tumor profiling market size reached US$ 11.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 24.6 Billion by 2032, exhibiting a growth rate (CAGR) of 8.6% during 2024-2032.
Cancer/tumor profiling, also known as biomarker testing, refers to a laboratory test or procedure used to identify specific proteins, genes or gene mutations (changes) and other biomarkers in a tumor tissue sample. It assists oncologists in determining if the pathways of a patient's tumor match up with the available targeted therapies. It also aids in routine diagnostics, therapeutic decision-making, and developing personalized treatment plans and therapies for individuals based on the severity of their ailment and genomic build-up. Cancer/tumor profiling also finds extensive applications in personalized medicine, research, the discovery of biomarkers, and the development of screening and diagnostic techniques.
Cancer/Tumor Profiling Market Trends:
Cancer/tumor profiling is widely used in oncology research and discovery of biomarkers during the process of drug design, discovery and development. As a result, the widespread prevalence of cancer across the globe represents the primary factor driving the market growth. Besides this, the growing focus on biomarkers for diagnosis and tumor profiling and the shifting preferences toward personalized medicine among the masses are augmenting the product demand. Additionally, there has been a significant rise in government funding and support for cancer research for the development of advanced techniques to reduce the time taken for the detection and identification of tumors. Along with this, the recent advancements in molecular biology techniques, such as next-generation sequencing (NGS), are accelerating the adoption of cancer/tumor profiling. Furthermore, the increasing investments by pharmaceutical and biotechnology companies in research and development (R&D) activities for the launch of novel therapies and new drug designing techniques are propelling the market growth. Other factors, including the rising number of clinical trials, growing adoption of immunoassay techniques, favorable reimbursement policies, improving healthcare infrastructure, and technological advancements, are also creating a positive outlook for the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global cancer/tumor profiling market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on cancer type, technology, technique and application.
Breakup by Cancer Type:
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma Cancer
Others
Breakup by Technology:
Next-Generation Sequencing (NGS)
Polymerase Chain Reaction (PCR)
Immunohistochemistry (IHC)
In-Situ Hybridization (ISH)
Microarray
Others
Breakup by Technique:
Genomics
Proteomics
Epigenetics
Metabolomics
Breakup by Application:
Personalized Medicine
Diagnostics
Biomarker Discovery
Prognostics
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Becton Dickinson and Company, Caris Life Sciences, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd, Hologic Inc., HTG Molecular Diagnostics Inc., Illumina Inc., Laboratory Corporation of America Holdings, NeoGenomics Laboratories, Qiagen N.V., Siemens AG and Sysmex Corporation.
Key Questions Answered in This Report
- 1. What was the size of the global cancer/tumor profiling market in 2023?
- 2. What is the expected growth rate of the global cancer/tumor profiling market during 2024-2032?
- 3. What has been the impact of COVID-19 on the global cancer/tumor profiling market?
- 4. What are the key factors driving the global cancer/tumor profiling market?
- 5. What is the breakup of the global cancer/tumor profiling market based on the cancer type?
- 6. What is the breakup of the global cancer/tumor profiling market based on the technique?
- 7. What are the key regions in the global cancer/tumor profiling market?
- 8. Who are the key players/companies in the global cancer/tumor profiling market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Cancer/Tumor Profiling Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Cancer Type
- 6.1 Breast Cancer
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Lung Cancer
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Colorectal Cancer
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Prostate Cancer
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Melanoma Cancer
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 Others
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
7 Market Breakup by Technology
- 7.1 Next-Generation Sequencing (NGS)
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Polymerase Chain Reaction (PCR)
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Immunohistochemistry (IHC)
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 In-Situ Hybridization (ISH)
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Microarray
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
- 7.6 Others
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
8 Market Breakup by Technique
- 8.1 Genomics
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Proteomics
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Epigenetics
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Metabolomics
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Application
- 9.1 Personalized Medicine
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Diagnostics
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Biomarker Discovery
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
- 9.4 Prognostics
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
- 9.5 Others
- 9.5.1 Market Trends
- 9.5.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Abbott Laboratories
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 Becton Dickinson and Company
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 Caris Life Sciences
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.4 Exact Sciences Corporation
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 Financials
- 15.3.4.4 SWOT Analysis
- 15.3.5 F. Hoffmann-La Roche Ltd
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.6 Hologic Inc.
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.6.4 SWOT Analysis
- 15.3.7 HTG Molecular Diagnostics Inc.
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
- 15.3.8 Illumina Inc.
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 Financials
- 15.3.8.4 SWOT Analysis
- 15.3.9 Laboratory Corporation of America Holdings
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 NeoGenomics Laboratories
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.11 Qiagen N.V.
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.11.3 Financials
- 15.3.11.4 SWOT Analysis
- 15.3.12 Siemens AG
- 15.3.12.1 Company Overview
- 15.3.12.2 Product Portfolio
- 15.3.12.3 Financials
- 15.3.12.4 SWOT Analysis
- 15.3.13 Sysmex Corporation
- 15.3.13.1 Company Overview
- 15.3.13.2 Product Portfolio
- 15.3.13.3 Financials
- 15.3.13.4 SWOT Analysis
